Cargando…

Differential Effects of Dietary Macronutrients on the Development of Oncogenic KRAS-Mediated Pancreatic Ductal Adenocarcinoma

SIMPLE SUMMARY: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease and oncogenic KRAS mutations are prevalent in PDAC patients. Oncogenic KRAS is critical for the initiation and development of PDAC; however, it alone is insufficient to drive pancreatic cancer. Oncogenic KRAS is an im...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Liang, Ji, Juntao, Ma, Jianjia, Wang, Dan, Liu, Muyun, Du, James Xianxing, Chen, Rong, Hou, Wei, Abbruzzese, James L., Logsdon, Craig D., Yang, Vincent W., Luo, Yongde, Lu, Weiqin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179355/ https://www.ncbi.nlm.nih.gov/pubmed/35681705 http://dx.doi.org/10.3390/cancers14112723

Ejemplares similares

Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity
por: Luo, Yongde, et al.
Publicado: (2021)

Obesogenic high-fat diet heightens aerobic glycolysis through hyperactivation of oncogenic KRAS
por: Wang, Dan, et al.
Publicado: (2019)

Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression
por: Chang, David Z, et al.
Publicado: (2012)

Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype
por: Fu, Yong, et al.
Publicado: (2015)

KRAS-related noncoding RNAs in pancreatic ductal adenocarcinoma
por: Yu, Shuang-Ni, et al.
Publicado: (2016)

Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma
por: Liu, Yu-Huei, et al.
Publicado: (2022)

KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
por: Zhang, Zining, et al.
Publicado: (2023)

Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
por: de Jesus, Victor Hugo Fonseca, et al.
Publicado: (2023)

Targeting Pancreatic Ductal Adenocarcinoma Acidic Microenvironment
por: Cruz-Monserrate, Zobeida, et al.
Publicado: (2014)

Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer
por: Singh, Kanchan, et al.
Publicado: (2020)

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy
por: Gurreri, Enrico, et al.
Publicado: (2023)

KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

Correction to: Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer
por: Singh, Kanchan, et al.
Publicado: (2021)

Notch1 Is Not Required for Acinar-to-Ductal Metaplasia in a Model of Kras-Induced Pancreatic Ductal Adenocarcinoma
por: Avila, Jacqueline L., et al.
Publicado: (2012)

Selective killing of cancer cells harboring mutant RAS by concomitant inhibition of NADPH oxidase and glutathione biosynthesis
por: Liu, Muyun, et al.
Publicado: (2021)

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
por: Luchini, Claudio, et al.
Publicado: (2020)

Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma
por: Ashok Kumar, Prashanth, et al.
Publicado: (2023)

Impact of KRAS Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma
por: Yousef, Abdelrahman, et al.
Publicado: (2023)

eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma
por: Chan, Karina, et al.
Publicado: (2019)

Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma
por: Venkat, Swati, et al.
Publicado: (2020)

Identification of FEZ2 as a potential oncogene in pancreatic ductal adenocarcinoma
por: Yang, Chaozhi, et al.
Publicado: (2022)

Oncogenic KRAS signalling in pancreatic cancer
por: Eser, S, et al.
Publicado: (2014)

Differential expression of RBM5 and KRAS in pancreatic ductal adenocarcinoma and their association with clinicopathological features
por: PENG, JIE, et al.
Publicado: (2013)

The Significance of Mitochondrial Dysfunction in Cancer
por: Luo, Yongde, et al.
Publicado: (2020)

Metastatic Pancreatic Cancer Is Dependent on Oncogenic Kras in Mice
por: Collins, Meredith A., et al.
Publicado: (2012)

CCAT2 is an oncogenic long non-coding RNA in pancreatic ductal adenocarcinoma
por: Cai, Yi, et al.
Publicado: (2018)

The Significance of Ras Activity in Pancreatic Cancer Initiation
por: Logsdon, Craig D., et al.
Publicado: (2016)

Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review)
por: Zhang, Joshua, et al.
Publicado: (2023)

Dual Inhibition of KRAS(G12D) and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma
por: Gulay, Kevin Christian Montecillo, et al.
Publicado: (2023)

Identification and functional analysis of novel oncogene DDX60L in pancreatic ductal adenocarcinoma
por: Wu, Hongjin, et al.
Publicado: (2021)

Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma
por: Topham, James T., et al.
Publicado: (2022)

KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence
por: Amintas, Samuel, et al.
Publicado: (2022)

Mutant KRAS Mediates circARFGEF2 Biogenesis to Promote Lymphatic Metastasis of Pancreatic Ductal Adenocarcinoma
por: Kong, Yao, et al.
Publicado: (2023)

Functional Significance and Therapeutic Potential of miR-15a Mimic in Pancreatic Ductal Adenocarcinoma
por: Guo, Shixiang, et al.
Publicado: (2019)

RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer
por: Kang, R, et al.
Publicado: (2014)

Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas
por: Salmón, Marina, et al.
Publicado: (2023)

Positive Crosstalk Between Hedgehog and NF-κB Pathways Is Dependent on KRAS Mutation in Pancreatic Ductal Adenocarcinoma
por: Wang, Yuqiong, et al.
Publicado: (2021)

PPDPF Promotes the Development of Mutant KRAS‐Driven Pancreatic Ductal Adenocarcinoma by Regulating the GEF Activity of SOS1
por: Ni, Qian‐Zhi, et al.
Publicado: (2022)

The Mutant p53-Driven Secretome Has Oncogenic Functions in Pancreatic Ductal Adenocarcinoma Cells
por: Butera, Giovanna, et al.
Publicado: (2020)

Spontaneously evolved progenitor niches escape Yap oncogene addiction in advanced pancreatic ductal adenocarcinomas
por: Murakami, Shigekazu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bgaekroo3q1ujfl74c835ivvcq